查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1820095

2025-2033 年血液系统恶性肿瘤市场报告（按类型、疗法、最终用户和地区）

Hematologic Malignancies Market Report by Type, Therapy, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球血液系统恶性肿瘤市场规模达651亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到1,295亿美元，2025-2033年期间的复合年增长率（CAGR）为7.55%。血癌发病率的不断上升、针对基因特征的标靶疗法和免疫疗法的日益普及，以及专注于血液系统癌症新型疗法的生物製药产品线的不断拓展，是推动市场成长的一些关键因素。

血液系统恶性肿瘤市场趋势：

血癌发生率上升

血癌发生率的上升和对新疗法开发的日益重视是推动血液系统恶性肿瘤市场成长的主要动力。根据 Globocan 2020 的数据，估计白血病的发生率在亚洲最高，2020 年诊断出 230,650 例，其次是欧洲 100,020 例和北美 67,784 例。因此，全球白血病的高发生率预计将推动血液系统恶性肿瘤市场的成长。同样，根据全球癌症观察站的数据，2020 年北美地区报告了近 67,784 例白血病和估计 35,318 例多发性骨髓瘤。根据白血病和淋巴瘤协会的数据，2021 年，美国估计共有 397,501 人患有或处于白血病缓解期。因此，预计市场上血癌病例的显着增加将推动预测期内血液系统恶性肿瘤市场价值的成长。

产品发布、合作伙伴关係和协作数量不断增加

许多公司正在实施各种策略性倡议，例如推出新产品、建立合作伙伴关係、促进合作以及参与併购，以增强其市场占有率。这反过来又对血液系统恶性肿瘤市场前景产生了正面影响。例如，2020 年 10 月，阿斯特捷利康製药印度公司宣布推出 Acalabrutinib 100 毫克胶囊，该胶囊以 Calquence 品牌用于治疗各种类型的白血病（白血病 (CLL) 和小淋巴细胞淋巴瘤）。同样，2024 年 1 月，塔塔纪念医院开发了印度首个治疗白血病的口服化疗药物。这项突破性进展有望彻底改变癌症治疗，特别是急性淋巴性白血病 (ALL) 等血液系统恶性肿瘤，提供比传统药片更精确、更适合儿童的替代品。预计此类创新将在未来几年增加血液系统恶性肿瘤市场的需求。

提高产品审批

各相关监管机构正在越来越多地批准血液系统恶性肿瘤药物，这为整体市场带来了积极的前景。例如，2020年9月，美国FDA批准了百时美施贵宝公司的氮胞苷（Onureg）300毫克片剂CC-486，用于继续治疗成人急性髓系白血病患者。同样，2021年3月，赛诺菲公司获得美国FDA批准，其Sarclisa（isatuximab）与卡非佐米和地塞米松联合用于治疗復发或难治性多发性骨髓瘤患者。同时，TG Therapeutics Inc. 于2021年2月获得美国FDA加速批准其UKONIQ（umbralisib）。 UKONIQ是一种口服、每日一次的磷酸肌醇3激酶（PI3K）δ和酪蛋白激酶1（CK1）ε抑制剂，用于治疗復发或难治性边缘区淋巴瘤（MZL）成年患者以及復发或难治性滤泡性淋巴瘤（FL）成年患者。获准治疗血癌的药物数量的显着增长，正在推动血液系统恶性肿瘤市场的价值成长。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球血液系统恶性肿瘤市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 白血病
  • 淋巴瘤
  • 多发骨髓瘤
  • 其他的

第七章：市场区隔：依疗法

  • 化疗
  • 放射治疗
  • 免疫疗法
  • 干细胞移植
  • 其他的

第 8 章：市场区隔：依最终用户

  • 医院
  • 诊断中心
  • 研究中心
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A4133

The global hematologic malignancies market size reached USD 65.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 129.5 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033. Growing prevalence of blood cancer, increasing adoption of targeted therapies and immunotherapies tailored to genetic profiles, and expansion of biopharmaceutical pipelines focusing on novel treatments for hematologic cancers are some of the key factors driving the growth of the market.

Hematologic Malignancies Market Trends:

Rising Prevalence of Blood Cancer

Escalating incidences of blood cancer and a growing emphasis on the development of new treatments are primarily driving the growth in the hematologic malignancies market. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America. Thus, the high incidence of leukemia worldwide is expected to drive the hematologic malignancies market growth. Similarly, according to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. According to the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, a prominent rise in blood cancer cases in the market is expected to propel the hematologic malignancies market value over the forecasted period.

Growing Number of Product Launches, Partnerships, and Collaborations

Numerous companies are implementing diverse strategic initiatives such as launching new products, forming partnerships, fostering collaborations, and engaging in mergers and acquisitions to enhance their market presence. This, in turn, is positively impacting the hematologic malignancies market outlook. For instance, in October 2020, AstraZeneca Pharma India announced the launch of Acalabrutinib 100 mg capsules, which are used for the treatment of various types of leukemias (leukemia (CLL) and small lymphocytic lymphoma) under the brand name Calquence. Similarly, in January 2024, Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets. Such innovations are projected to augment the hematologic malignancies market demand in the coming years.

Increasing Product Approvals

Various concerned regulatory authorities are increasingly approving hematologic malignancies drugs, which is creating a positive outlook for the overall market. For instance, in September 2020, the US FDA approved Bristol Myers Squibb's azacytidine (Onureg) 300 mg tablets, CC-486, to continue treating adult patients with acute myeloid leukemia. Similarly, in March 2021, Sanofi SA received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. In line with this, in February 2021, TG Therapeutics Inc. received the US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL). Significant growth in number of approved drugs for treating blood cancer is propelling the hematologic malignancies market value.

Global Hematologic Malignancies Industry Segmentation:

Breakup by Type:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others

The hematologic malignancies market report has provided a detailed breakup and analysis of the market based on the type. This includes leukemia, lymphoma, multiple myeloma, and others.

Leukemia is a type of hematologic malignancy, also known as blood cancer, that originates in the bone marrow and affects the production of blood cells. The rising cases of leukemia across the globe are bolstering the hematologic malignancies market share. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America.

Furthermore, the significant rise in the multiple myeloma market is a clear indication of the need for increased research and development. For instance, according to the Global Cancer Observatory, in 2020, nearly 35,318 cases of multiple myeloma were reported in the North American region. This rise in multiple myeloma cases underscores the importance of your work and is positively influencing the hematologic malignancies market price trends.

Breakup by Therapy:

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

As per the hematologic malignancies market overview by IMARC, for most types of blood cancers, chemotherapy is the common treatment. The large patient pool and the increasing incidence of blood cancers are the major drivers augmenting the need for chemotherapy. For instance, in June 2019, the United States Food and Drug Administration granted approval to Polivy to be used in combination with the chemotherapy drug bendamustine and rituximab to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

Breakup by End User:

  • Hospitals
  • Diagnostics Centers
  • Research Centers
  • Others

The hematologic malignancies market research report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostics centers, research centers, and others.

Hospitals are primary end users in the hematologic malignancies market, providing diagnosis, treatment, and ongoing care for patients with blood cancers, such as leukemia, lymphoma, and myeloma. They offer a range of specialized services, including chemotherapy, radiation therapy, stem cell transplantation, and supportive care. Hospitals also serve as centers for clinical trials and research, driving advancements in treatment options and patient outcomes.

Diagnostics centers are essential for early detection and monitoring of hematologic malignancies through a variety of tests, including blood tests, bone marrow biopsy, imaging studies, and genetic testing. These centers provide accurate diagnostic services, enabling healthcare providers to initiate timely treatment strategies. Diagnostics centers often collaborate closely with hospitals and oncology clinics to ensure comprehensive patient care and management throughout the treatment journey.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.

Besides this, hematologic malignancies market statistics indicates that the presence of key players, the high prevalence of blood cancer patients, established healthcare infrastructure, and the availability of branded drugs in North America and Asia Pacific countries are positively impacting the hematologic malignancies industry. According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. As per the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, the increasing number of blood cancer cases in the region is a major driving factor for the growth of the market. Besides this, hematologic malignancies market forecast by IMARC indicates that beneficial government initiatives and an increase in the number of research partnerships are further contributing to the market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly US$ 17 Million in research grants to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the detailed profiles of the following key players:

  • AbbVie Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report:

  • How big is the hematologic malignancies market?
  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hematologic Malignancies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Leukemia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Stem Cell Transplantation
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck & Co. Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
  • Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2024
  • Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2024
  • Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
  • Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
  • Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Hematologic Malignancies Market: Competitive Structure
  • Table 7: Global: Hematologic Malignancies Market: Key Players